When treated with the SLC1A5 inhibitor L-γ-glutamyl-p-nitroanilide (GPNA), different molecular subtypes of breast cancer cells, including luminal, basal-like, and claudin-low, showed significant inhibition of glutamine uptake (van Geldermalsen et al., 2016). Here, SLC1A5 is linked to breast carcinoma.